|
- April 25, 2014 - press release
Dr. Shikha P. Barman, Integral BioSystems LLC Chief Executive Officer, Chief Technology Officer, and recipient of the prestigious award naming her “One of the 20 Women to Watch in 2014” by Mass High Tech, will lead her firm’s participation in the ARVO 2014 Annual Meeting in Orlando, Florida, May 4 – 7, 2014. To be located in Booth #644, the Boston area startup ophthalmic pharmaceutical formulation firm and CRO will present three technical posters as well as answer potential clients’ questions about its proprietary ophthalmic formulation platforms OcuSurf™ and EySite™.
 read more
- April 4, 2014 - press release
Dr. Shikha Barman, Chief Executive Officer and Chief Technology Officer of the startup Boston-area specialty pharmaceutical formulation development firm and CRO Integral BioSystems LLC, will be awarded the prestigious title of “One of the 20 Women to Watch in 2014” by Mass High Tech on May 8, 2014 at the Sheraton Boston Hotel.
read more
- April, 2014 - newsletter
Boston Area Specialty Pharmaceutical Formulation Development Firm Integral BioSystems LLC Founder and CEO/CTO Dr. Shikha Barman to be feted as "One of the 20 Women to Watch in 2014" by Mass High Tech.
read more
- February, 2014 - newsletter
Boston-area specialty drug delivery CRO Integral BioSystems has expanded its service offerings to include formulation development for generics using the Quality by Design (QBD) methodology now required by the FDA. This offering is in addition to innovation-driven drug delivery projects to repurpose marketed drugs for 505(b)(2) regulatory submissions in multiple indications for dermatologics, ophthalmics, CNS products, intranasals and injectables. Compounds developed are small molecules, proteins, peptides, nucleic acids and biosimilars. While the company has developed all forms of dosage formats, core specialization is in "hard-to-develop" dosages such as biodegradable microspheres, liposomes, nano-coacervates and micro- and nano-crystals, including working out scale-up process parameters. The company has fully equipped analytical and process development laboratories, with state-of-the-art equipment and a core development team of formulation development, process development and analytical methods scientists. The company offers high quality, focused and efficient science.
read more
- October 25, 2013 - press release
Integral BioSystems LLC now has exclusive rights to the name it coined for its ophthalmic platform pharmaceutical formulation development product, OcuSurf™, offering an innovative approach for those interested in developing ophthalmic medications with enhanced persistence and bioavailability for front-of-the-eye application.
Integral BioSystems LLC, led by 20+ year veteran of drug formulation development Shikha P. Barman, Ph.D., now offers clients formulation services utilizing Integral’s novel, front-of-the-eye platform OcuSurf™. Designed to enhance the persistence and bioavailability of ophthalmic formulations, Integral BioSystems is ready help clients to incorporate the advantages of OcuSurf™ into their products.
read more
- August 31, 2013 - press release
Come discuss your preclinical needs with Integral BioSystems CEO/CSO Shikha P. Barman, Ph.D. at the Hyatt Regency in New Brunswick, NJ, September 19 and 20, 2013 to discuss how Integral BioSystems’ pharmaceutical formulation capabilities can help your firm to develop medications for the treatment of disease of the front and back of the eye using the firm’s advanced platform ophthalmic formulation technologies.
Integral BioSystems LLC, led by 20-plus-year veteran of drug formulation development Shikha P. Barman, Ph.D., will offer potential clients advice on the use of Integral’s novel, platform front-of-the-eye and back-of-the-eye ophthalmic therapeutic delivery systems, OcuSurf™ and EySite™.
read more
- July, 2013 - newsletter
Welcome to the Integral BioSystems Monthly Newsletter, to be released every month. The newsletter will contain our service offerings, updates to our organization, news releases and/or announcements of innovations, etc. Additionally, Integral staff will publish white papers on topics of interest to the drug development community. The topic of interest for this newsletter is "Drug Repurposing : An Integrated IP/Formulation Development Strategy".
read more
- June 29, 2013 - press release
In response to increased client demand and the expansion of the company’s internal product development programs, Integral BioSystems has expanded both its laboratory and office facilities to accommodate a 33 percent increase in headcount with attendant increase in its analytical equipment holdings
The markets have spoken, and Integral BioSystems LLC, led by 20+ year veteran of drug formulation development Shikha P. Barman, Ph.D., with its recent expansion of facilities and personnel, is now better able to meet the ever-increasing demands of externally and internally driven drug formulation development projects.
read more
- June 25, 2013 - press release
Integral BioSystems CEO/CSO Shikha P. Barman, Ph.D. will be on hand at the Hyatt Regency in New Brunswick, NJ September 19 and 20, 2013 to discuss Integral BioSystems’ pharmaceutical formulation capabilities including developing medications for the treatment of disease of the front and back of the eye using the firm’s advanced platform ophthalmic formulation technologies.
Integral BioSystems LLC, led by 20+ year veteran of drug formulation development Shikha P. Barman, Ph.D., will offer potential clients advice on the use of Integral’s novel, platform front-of-the-eye and back-of-the-eye ophthalmic therapeutic delivery systems, OcuSurf™ and EySite™.
read more
- May 28, 2013 - press release
In response to client requests, Integral BioSystems is developing and will be licensing Integral’s novel platform ophthalmic formulation technologies for use in treatment of disease in both the front and the back of the eye.
Integral BioSystems LLC, led by 20+ year veteran of drug formulation development Shikha P. Barman, Ph.D., is developing and will offer for license its novel, platform front-of-the-eye and back-of-the-eye ophthalmic therapeutic delivery systems, OcuSurf™ and EySite™.
read more
- May 05, 2013 - press release
Integral BioSystems will exhibit and offer its drug development expertise to attendees at the ARVO Annual Meeting at the Washington State Convention Center in Seattle, WA from May 5, 2013 through May 9, 2013 in Exhibitor Booth #517.
The 2013 Meeting of the Association for Research and Vision in Ophthalmology, being held at the Washington State Convention Center in Seattle, WA combines a wide range of talks from commercial and academic figures in ophthalmological science, poster presentations about recent developments in ophthalmology, and offers of ophthalmology-related products and services. Integral BioSystems LLC, led by 20+ year veteran of drug formulation development Shikha P. Barman, Ph.D. and VP of Operations/Intellectual Property Dave Karasic, Esq., will be on hand to answer questions about the firm and its capabilities, which include ophthalmological pharmaceutical formulation development and its related intellectual property issues.
read more
- April 15, 2013 - article
A fascination with medical polymer applications sparked her launch of an R&D incubator
Growing up in Calcutta, Shikha P. Barman had always dreamed of making a contribution to medicine. After bravely moving to the U.S. at age 18 to earn degrees in chemistry, polymer science, and plastics engineering, she found her niche in medical applications of polymers and went to work for a series of start-ups in that field. Before long, she says, the “entrepreneurial seed was planted.” She began mapping out a plan to create an R&D incubator that would help small to midsized companies develop their drugs into innovative dosage forms.
read more
- April 02, 2013 - press release
Dr. Shikha Barman, Founder of Boston Area Specialty Pharmaceutical Formulation Development Firm Integral BioSystems LLC, will be a Subject in ACS Publication "Chemical and Engineering News" April 15 Edition Article about Woman Scientist Entrepreneurs
Upon completion of her graduate studies in classical Physical and Polymer Chemistry at the University of Massachusetts - Lowell, Dr. Shikha Barman spent the ensuing 20 years of her career exploring and perfecting methods utilizing polymers in medicine, making pioneering contributions to such endeavors as sustained release drug delivery systems, targeting drugs selectively to specific cells at a specific site, enhancing drug bioavailability, and the use of polymers as “scaffolds” to grow cells and organs. After producing related novel intellectual property for a succession of startup firms owned by others, she began her own pharmaceutical formulation consultancy in 2009, Integral BioSystems LLC, which in 2012 grew to incorporate a full-capability specialty pharmaceutical development laboratory. Accordingly, the American Chemical Society publication Chemical and Engineering News will feature Dr. Shikha Barman in its “Diversity” Calendar Feature in the April 15, 2013 issue.
read more
- April 01, 2013 - press release
Boston Area Specialty Pharmaceutical Formulation Development Firm Integral BioSystems LLC Founder and CEO/CTO Dr. Shikha Barman to be Featured in CEOCFO Magazine Article.
An interview with Dr. Shikha Barman, Chief Executive Officer and Chief Technology Officer of the startup Boston-area specialty pharmaceutical formulation development firm Integral BioSystems LLC, will soon appear in CEOCFO magazine. The focus will be on Dr. Barman's role as the entrepreneurial head of this cutting-edge drug development firm producing state-of-the-art microparticulate and nanoparticulate-based drug dosage forms, both under contract for third parties as well as for her firm’s own products.
read more
- February 20, 2013 - press release
Integral BioSystems will participate in MassBio’s 2nd Annual Massachusetts CRO/CMO Symposium on Monday, February 25, 2013 from 7:30AM to 6:00PM at the Boston Marriott Newton located at 2345 Commonwealth Avenue, Newton, MA 02466.
Integral BioSystems LLC, led by 20+ year veteran of drug formulation development Shikha P. Barman, Ph.D. and VP of Operations/Intellectual Property Dave Karasic, Esq., will be on hand to answer questions about the firm and its capabilities. The Massachusetts CRO/CMO Symposium, organized by MassBio, is designed to bring together the biopharmaceutical industry and the Massachusetts CRO/CMO cluster. The event will showcase the roles these types of partnerships are playing in accelerating drug development.
read more
- February 02, 2013 - press release
In response to client requests, Integral BioSystems now offers a formulation development program combining a pre-development study to determine the potential intellectual property pitfalls related to proposed client development projects.
Integral BioSystems LLC, led by 20+ year veteran of drug formulation development Shikha P. Barman, Ph.D., has teamed up with intellectual property firm Patents Etcetera to offer an integrated, practical approach to the development of repurposed drugs for a new indication. While regulatory hurdles are fewer with the repurposing of drugs with a well-established safety profile in humans, IP concerns around these products are significant. Prior to embarking on reformulating and redeveloping the drug for a new indication, it is strategically prudent to start the process with IP strategy to examine approaches in drug delivery to gain patent protection for the new dosage form and indication. Integral BioSystems/Patent Etcetera now offer this service.
read more
- September 18, 2012 - press release
Boston area intellectual property (IP) firm Patents Etcetera and contract research organization (CRO) pharmaceutical development firm Integral BioSystems have joined forces in offering drug development services that start with an IP strategy review.
According to the CEO of Integral BioSystems, LLC, Shikha P. Barman, Ph.D., instead of investing dollars and time in a lengthy approval process for a new chemical entity (NCE), pharmaceutical companies are seeking to reduce risks and costs by finding new uses for existing products. Companies that take this approach fit naturally within the risk reduction model because they start with approved compounds with established history of use in humans. This approach to drug development, using repurposed, already-approved compounds, can make it possible for new drug formulations to enter the clinical development phase more rapidly and at much lower cost than when NCEs are used.
read more
|
|
